Alnylam Pharmaceuticals (ALNY) Common Equity (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Common Equity data on file, last reported at $1.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 152.35% year-over-year to $1.1 billion; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (up 152.35% YoY), and the FY2025 full-year result was $789.2 million, up 1076.33% from the prior year.
• Common Equity for Q1 2026 stood at $1.1 billion, up from $789.2 million in the prior quarter.
• Across five years, Common Equity topped out at $1.1 billion in Q1 2026 and bottomed at -$408.1 million in Q2 2023.
• The 5-year median for Common Equity is $32.4 million (2024), against an average of $114.7 million.
• The widest annual swing landed in 2023, when Common Equity slumped 331.84%; it then surged 8270.56% in 2025.
• A 5-year view of Common Equity shows it stood at -$158.2 million in 2022, then sank by 39.45% to -$220.6 million in 2023, then soared by 130.41% to $67.1 million in 2024, then surged by 1076.33% to $789.2 million in 2025, then surged by 36.27% to $1.1 billion in 2026.
• The last three Common Equity figures came in at $1.1 billion (Q1 2026), $789.2 million (Q4 2025), and $233.9 million (Q3 2025), per Business Quant data.

Peer Comparison